ArticleBMC health services research2025
The impacts of the national volume-based procurement policy on the chronic disease medication market in China's public hospitals: a case study of medications for diabetes.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Analysis of the impact of national centralized volume-based procurement drug policy on the market dynamics of tuberculosis drugs.BMC health services research · 2026Article
- Has volume-based procurement reduced household catastrophic health expenditure in rural patients with chronic disease?-Evidence from CHARLS 2018 and 2020 in China.Health economics review · 2026Article
- The Contingent Payoff of Transparency: The Mediating Roles of Citizen Participation and Enforcement in Health Service Delivery Improvement.Journal of evaluation in clinical practice · 2026Review
- Medication Discrepancy in the Hospital-to-Home Transition Period of Elderly Chinese Patients with Coronary Heart Disease: A Qualitative Study.Patient preference and adherence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe exorbitant cost of chronic disease medications poses a shared challenge for healthcare systems worldwide. China introduced the national volume-based procurement (NVBP) policy in 2018, aiming to leverage market mechanisms to lower medication costs and rationalize prescription patterns. Using oral antidiabetic drugs as a case study, this study analyzes the comprehensive impact of NVBP policy on the chronic disease medication market in Chinese public hospitals.
methodsData were obtained from the NVBP platform, encompassing procurement records from public hospitals across China from January 2018 to December 2022. (by month and province). The study selected oral antidiabetic drugs from the previous five NVBP batches as the sample, applying the anatomical therapeutic chemical/defined daily dose (ATC/DDD) method to standardize medication consumption (defined daily doses, DDDs) and expenditure (defined daily cost, DDDc). Price changes were assessed by Price index, drug consumption and expenditure were analyzed by quantity and cost indices, the influence on market structure was assessed by drug spending and sales proportions and market concentration rate. Interrupted time series (ITS) analysis was applied to quantify the policy effects.
resultsThe overall price of oral antidiabetic drugs decreased significantly by approximately 60% (P < 0.001) after the implementation of NVBP policy, with prices of bid-winning drugs dropping by 74.2% (P < 0.001) and non-winning drugs by 50.3% (P < 0.001). The total drug quantity index ([Formula: see text]) increased by 86.1%, while the total drug expenditure variation index ([Formula: see text]) decreased by 50.2% (P < 0.001), particularly the consumption of bid-winning drugs surging by 1094.1% (P < 0.001). The expenditure substitution rate of generic drugs increased from 62 to 73%, with the market substitution rate increased from 71 to 88%. Market concentration rate significantly decreased, with Concentration Ratio 5 (CR5) declining by 23.6% and Herfindahl-Hirschman Index (HHI) declining from 0.11 to 0.07 (P < 0.001), suggesting that market competition became more dispersed.
conclusionsThe NVBP policy effectively reduced the expenditures of chronic disease drugs, enhances therapeutic availability, and promoted the replacement of brand-name drugs by generic drugs. Rather than leading to a market monopoly, the policy enhanced competition in the antidiabetic drug sector, serving as an empirical reference for other countries seeking to resolve drug cost challenges through centralized procurement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.